AI in Clinics and Hospitals, Along with FDA Steps Signal Opportunity for Early Mover Advantages
Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – The healthcare industry’s ongoing revolution involving artificial intelligence (AI) is multi-faceted, with experts pushing for AI-enhanced patient outcomes, and not just efficiency for providers. As recent surveys show 85% of healthcare execs expect AI to increase efficiency, while healthcare systems are easing challenges with responsible approaches to innovation and AI. Serious capital is flowing into the AI healthcare space, with private healthcare innovator Persivia recently receiving $107 million to expand its AI-driven healthcare platform. Behind the scenes, several other developments in digital healthcare tech are emerging, from players such as Avant Technologies, Inc. (OTCQB: AVAI), UnitedHealth Group (NYSE: UNH), CeriBell, Inc. (NASDAQ: CBLL), Weave Communications, Inc. (NYSE: WEAV), and Becton, Dickinson and Company (NYSE: BDX).
A new survey from PYMNTS Intelligence found that 9 in 10 healthcare executives at billion-dollar firms are already seeing ROI from their generative AI rollouts. By 2035, analysts believe AI could add another $461 billion in value to a healthcare industry already on track to surpass $2.26 trillion.
Avant Technologies, Inc. (OTCQB: AVAI), is making headway in the AI healthcare space through its joint venture with Ainnova Tech. Operating under Ai-nova Acquisition Corp. (AAC), the venture holds global rights to VisionAI, a cutting-edge screening platform and hardware system. The companies recently announced that the FDA has officially received their request for a pre-submission meeting—an early but essential step in the regulatory pathway toward potential U.S. market clearance.
This development puts Avant on a stronger path toward unlocking larger commercial markets. VisionAI combines retinal scans, patient vital signs, and AI algorithms to flag early signs of serious chronic conditions, including diabetic retinopathy, cardiovascular disease, liver fibrosis, kidney disease, and type 2 diabetes. Research shows that AI tools like VisionAI can detect warning signs with over 90 percent sensitivity, often identifying problems before traditional symptoms emerge, according to the NIH.
"This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where VisionAI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,” said Vinicio Vargas, CEO at Ainnova and a member of AAC's Board of Directors. “Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product."
The upcoming FDA meeting is a key milestone. It will help define the clinical trial roadmap and lock in the regulatory path needed for VisionAI to enter the U.S. healthcare market under a 510(k) submission. If successful, this step could clear the way for much wider adoption.
Unlike many early-stage AI healthcare companies, AVAI already has its technology in use. VisionAI is actively running in pilot programs across Latin America, including in Chile, Mexico, Brazil, and the Dominican Republic. These early deployments are producing real-world patient data and showing how early screening can lower overall healthcare costs while improving outcomes in everyday clinics.
Recently, AAC added four new diagnostic algorithms to its portfolio, licensed from one of Asia’s largest healthcare networks. These AI models were trained and validated on over 2.3 million clinical cases and are now built into VisionAI to boost its accuracy across a wide range of chronic conditions.
To support its U.S. regulatory push, Avant’s partner Ainnova has enlisted Fortrea, a global contract research organization (CRO) with deep FDA experience. With early traction in emerging markets and U.S. regulatory steps underway, Avant appears to be following a smart two-track strategy: building real-world adoption where approvals are faster, while setting up for longer-term growth in the world’s most valuable healthcare market.
For investors keeping an eye on small-cap innovators in healthcare AI, Avant is starting to check some important boxes. It already has a working product, real-world deployments, and a regulatory process in motion. With global licensing secured and U.S. market access on the horizon, Avant Technologies stands out as one of the few early-stage names already moving from concept to execution.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
UnitedHealth Group (NYSE: UNH) has pushed AI integration further than nearly any peer, with 1,000 applications currently in production across its business lines. These range from claims automation and visit transcription to internal code generation used by 20,000 engineers.
Half of these systems now use generative AI, underscoring how deeply embedded the tech has become in core operations. While questions remain around ethics and regulatory oversight, UnitedHealth’s scale in AI healthcare delivery is unmatched in the industry.
CeriBell, Inc. (NASDAQ: CBLL) just became the only medical device company in the U.S. to receive FedRAMP High authorization—allowing its AI-powered EEG system to be securely deployed across federal healthcare systems.
"The FedRAMP High authorization underscores Ceribell’s leadership in both medical innovation and information security," said Jane Chao, Ph.D., co-founder and CEO of Ceribell. "It places us in the company of leading cloud and technology organizations that have met the most stringent federal cybersecurity standards. More importantly, this designation enables broader deployment of our rapid EEG system, to equip clinicians throughout federal healthcare networks with the tools they need to deliver faster diagnoses and more informed treatment decisions."
This includes rapid rollout to VA hospitals, enabling faster seizure diagnosis for high-risk patients like veterans. The clearance marks a major win for Ceribell’s brain monitoring platform, combining real-time AI analytics with elite-level cloud security.
Weave Communications, Inc. (NYSE: WEAV) just acquired TrueLark to bring conversational AI directly into the front office of healthcare practices—starting with the one thing every patient still uses: the phone.
"TrueLark represents more than a new product, the acquisition positions Weave at the forefront of agentic AI in SMB healthcare," said Brett White, CEO of Weave. Their purpose-built, AI-first platform brings autonomous, always-on functionality to core front-office operations. The acquisition will deliver a virtual assistant that helps practices fill more appointments, improve responsiveness, and drive stronger patient engagement, all without increasing headcount."
Instead of waiting on hold, patients can now book, rebook, and get questions answered via intelligent, voice-based automation. For small and mid-sized clinics, this could be the upgrade that finally cuts through burnout and bottlenecks.
“The experience of engaging or scheduling or rebooking or getting answers to your questions from your healthcare practice … is not very modern,” said Marcus Bertilson, COO of Weave in an interview with PYMNTS. “The consumer expects immediate answers, but you have to usually wait online… In the future, the future of a healthcare practice — this is just embedded. Anyone who asks you to call in and wait online … will just fall behind.”
Becton, Dickinson and Company (NYSE: BDX) recently launched the HemoSphere Alta™, an advanced AI-driven hemodynamic monitoring platform designed to help clinicians detect and prevent dangerous drops in blood pressure during surgery.
"HemoSphere Alta™ marks the latest milestone in our continuum of connected care innovations by redefining the clinician experience with more efficient workflows and increased usability," said Tim Patz, president of BD Advanced Patient Monitoring. "These AI-driven enhancements of advanced algorithms and machine learning provide clinicians with more insights and clinical decision support to help improve the quality of care for their patients."
The system introduces first-of-its-kind features like the Cerebral Autoregulation Index, which provides personalized insights into a patient’s brain blood flow stability. With predictive capabilities and hands-free controls, HemoSphere Alta is positioned to raise the standard for smart, connected care in critical care environments.
CONTACT:
Baystreet.ca
(250) 661-3391
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
